The biggest oil shock ever. Pharma broke the Dow

Rundown · 2026-09-09

Two things happened on Tuesday and only one of them was about oil. The IEA now says the volume of supply offline exceeds the 1973 shock — the largest disruption in the history of the oil market — after Houthi missiles and drones hit Saudi energy facilities. But the Dow fell 628 points, or 1.18%, against the Nasdaq's 0.32%, and that gap was not crude. A failed Novartis trial took Amgen down 10% and repriced an entire drug class.

Market Performance

• Dow: 52,786.07 (-1.18%) — -628.18 pts, more than triple the Nasdaq's percentage loss
• S&P 500: 7,673.52 (-0.58%) — -45.08 pts
• Nasdaq: 26,421.41 (-0.32%) — -85.58 pts
• Russell 2000: 2,960.20 (-0.52%) — -15.44 pts
• 2Y: 4.394%, up about 1.5bp · 10Y: 4.796%, up about 1.2bp — both barely moved
• WTI settled $93.03 (+1.69%) — up $1.55 · Brent near $98.50 (+2.3%) after touching about $99
• Gold: $4,439.00 (-0.84%) — down $37.60 · Bitcoin $79,060 (+0.84%) · Copper hit an all-time high
• Energy, semiconductors and nuclear power led; healthcare was the wreck, with XLV down 2.52% against SPY's 0.37%

That last line is the whole session. A 2.52% drop in healthcare against a 0.37% drop in the broad market is not a macro day — it is a sector event wearing a macro costume. The oil move was real and it deserves the coverage it got, but it is not what took 628 points out of the Dow.

The Dow's Problem Wasn't Oil

• Novartis fell about 14% to $137.63, heading for one of its worst days on record, after its third clinical setback in a week
• The headline failure: pelacarsen, developed with Ionis, missed its primary endpoint in a Phase III trial of 8,323 patients. It successfully lowered Lp(a) — it just did not reduce cardiovascular death, non-fatal heart attack, non-fatal stroke or urgent revascularisation
• The second: del-desiran, acquired through Avidity, failed to beat placebo in the Phase III HARBOR study in myotonic dystrophy type 1 — roughly 150 patients over 54 weeks, missing on video hand opening time
• The read-across did the damage. Pelacarsen lowered the biomarker and did not improve outcomes, which calls into question whether lowering Lp(a) helps at all — and that is a question about a whole class, not a molecule
• So Amgen fell 10% to $394.38 on its own Lp(a) candidate, olpasiran, currently in the Phase 3 OCEAN(a)-Outcomes trial. Eli Lilly fell 2% on the same logic. Dyne and Sarepta were dragged along
• Amgen announced positive Phase 3 data in small cell lung cancer the same morning and still fell 10%. Good news from its own pipeline could not outweigh bad news from someone else's trial
• Now do the index arithmetic. The Dow is price-weighted, and Amgen is one of its highest-priced members at nearly $400 a share. A $44 decline in a single high-priced constituent moves that index far more than it moves the S&P, where Amgen is weighted by market value. That is the mechanical reason the Dow lost 1.18% while the Nasdaq lost 0.32%
• The lesson is old and keeps being relearned: the Dow is not a measure of the market, it is a measure of thirty share prices — and on a day when one of the priciest of them drops 10%, the index tells you about that stock, not about the economy

Bigger Than 1973

• Yemen's Houthis launched a broad offensive on Saudi energy infrastructure, hitting Aramco facilities at Abha, Najran and Jizan and an air base at Khamis Mushait with ballistic missiles and drones
• Fires broke out, operations at some facilities were halted, and 73 people were wounded. Saudi authorities called it a dangerous escalation
• The Jizan facility matters most: it is a roughly 400,000 barrel-a-day refinery, one of the kingdom's largest — and, as of yesterday's post, it had already been struck twice in the past month
• WTI settled at $93.03 and Brent touched about $99 before easing back to around $98.50
• And here is the number that should reset everyone's frame. The IEA now says the volume of fuel supply offline exceeds the supply loss during the 1973 oil shock — the largest supply disruption in the history of the global oil market
• The supporting figures: global oil supply is projected to fall 4.3 million barrels a day on average across 2026, then rebound 8.3 mb/d next year to 110.3 mb/d. Regional exports, including routes bypassing Hormuz, have fallen 2.1 mb/d to 15 mb/d since the Strait was effectively closed again in early July
• Hold that against the tape. The largest oil supply disruption ever recorded, and the S&P 500 is still up 12.1% year to date. Either the equity market has decided this resolves, or it has not finished pricing it

The Data Nobody Is Pricing

• August PPI lands Thursday and August CPI on Friday — the final inflation readings before the September 15-16 meeting
• The market assigns roughly a 58% probability to a hike. That number has barely moved since Friday's payrolls print
• But look at what core inflation is actually doing. Core CPI rose at a 1.6% annualised rate over the three months through July, down from 2.3% — its first sub-2% reading this year, and below the Fed's target
• Annual core CPI in July was 2.5%, and headline CPI 3.4%. Do not confuse the measures: core PCE, which the committee steers by, is running 3.3%, and headline PCE 3.7%. They tell different stories and the gap between them is unusually wide
• So the honest summary of the position is uncomfortable. On a three-month basis, the Fed's core consumer inflation trend is running below target. On a twelve-month basis it is not. And the input that would push it back up — energy — is in the middle of the biggest supply disruption on record
• That is why Friday matters more than usual. A soft core print gives the doves a live argument for the first time in weeks. A firm one, with Brent at $99, ends the debate
• The catch we flagged yesterday still stands: Friday's report covers August. Brent at $99 and record diesel happened in September. The committee will be reading last month's number in this month's world

Notable Movers

• (NVS) -14% to $137.63 — Three trial setbacks in a week; one of its worst sessions on record
• (AMGN) -10% to $394.38 — Punished for someone else's failed trial, on the same morning it reported positive Phase 3 lung cancer data. The single biggest reason the Dow underperformed
• (CRWV) +11.7% to $99.83 — CoreWeave rallied to just under $100 with the neocloud complex. Worth being precise about the catalyst: there was no CoreWeave-specific release. The moves cited around it were OpenAI's GPT-6 Astra launch, a Nebius-Palantir sovereign AI partnership, and Commerce Department investments in quantum names. The $8.5B GPU-backed loan doing the rounds is from March, not this week
• (INTC) +9% — On reports of planned processor price increases
• (QCOM) +8% — Qualcomm rallied on a multi-generational AI chip agreement with Amazon, arguably the most consequential corporate item of the day and one that went largely unremarked
• (BE) +10% — Bloom Energy confirmed for S&P 500 inclusion before the open on September 21, alongside Illumina and Everpure, replacing Molson Coors, Trade Desk and Builders FirstSource. UBS raised its target to $325 from $300, lifting its multiple specifically to reflect the index add
• (ORCL) +5% — Ahead of earnings
• (PTON) -6.8% — Morgan Stanley cut Peloton to Underweight with a target near $4.50, analyst Nathan Feather arguing the headwinds are structural rather than cyclical: new subscriber additions are down 78% from their pandemic peak, with churn compounding it

Cross-Asset

The oil move was macro. The index move was not.

Asset · Level · Change · Driver

Dow Jones · 52,786.07 · -1.18% · Amgen and price weighting

Nasdaq · 26,421.41 · -0.32% · Semis and neoclouds held it up

Healthcare, XLV · sector ETF · -2.52% · Lp(a) class repriced

WTI crude · $93.03 · +1.69% · Houthi strikes on Saudi sites

Brent crude · near $98.50 · +2.3% · Touched about $99 intraday

10-Year yield · 4.796% · +1.2 bps · Bonds ignored all of it

• The bond market's non-reaction is the tell. Yields moved a basis point on a day the IEA declared the largest oil disruption in history. Rates traders are waiting for Friday, not for headlines
• Copper made an all-time high on tariff concerns, which is a second industrial-cost signal running alongside diesel
• Gold fell 0.84% despite the escalation — for the second session running it has behaved like a rates instrument, not a haven

Private Dealmaking

• Mistral (French AI lab) raised about $3.5B (€3B) at a valuation above €21B, led by Samsung Electronics, co-led by the EU's Scaleup Europe Fund and PSG Equity — the largest equity round ever raised by a European technology company
• Stoke Space (fully reusable rockets · Series E co-led by Point72 Ventures and Spark Capital, taking total funding to $2.3B; first orbital launch targeted for early 2027) — $1B
• Apollo agreed to buy $500M of Series A convertible preferred in Cumberland Farms, a pre-IPO private placement ahead of a New York listing; the shares convert at 115% of the eventual IPO price
• The Exploration Company (reusable cargo spacecraft · Series C co-led by Bessemer, Atomico and the Scaleup Europe Fund, the largest Series C ever raised by a European space company) — $450M
• Forus (the AI network connecting doctors, pharmacies, payers and biopharma · Series C led by Bain Capital Ventures at a $3B valuation, roughly triple its Series B mark from months earlier) — $150M
• Split Pay (splits monthly rent and mortgage payments into two instalments while landlords and servicers are paid in full and on time · back-to-back Series A and B, both led by Khosla Ventures) — $125M

Three of these have the same fingerprint. The EU's Scaleup Europe Fund co-led both Mistral and The Exploration Company on the same day, and Samsung led the largest technology round in European history — while a Nebius-Palantir "sovereign AI" deal was moving CoreWeave. Sovereign and strategic capital, not venture capital, is now setting the price in European technology. Note also that Samsung is one of the three semiconductor names responsible for a large share of this year's emerging-market rally, and it just spent €3 billion buying into a European model lab.

What To Watch

• Thursday: August PPI. Friday: August CPI, 8:30am ET. Then the FOMC on September 15-16
• Friday's core print is the fulcrum. With three-month annualised core CPI at 1.6% and hike odds at 58%, the market and the recent trend are pointing in opposite directions
• Watch whether Brent closes above $100. It touched roughly $99 on Tuesday and has not settled in triple digits this cycle
• Watch Saudi damage assessments. Halted operations at Abha, Najran and Jizan are the difference between a headline and an actual barrel count
• Canada's counter-tariffs are now live, with rates up to 50% on roughly $20-27B of US goods including dairy, steel and wood products. Copper at a record is the first place that shows up
• Oracle reports after Tuesday's 5% run-up, and it is now one of the cleaner reads on whether AI infrastructure spending is still accelerating

TLDR

• Dow -628.18 (-1.18%) against Nasdaq -0.32% — the gap was a drug trial, not oil
• Novartis -14% on its third setback in a week; pelacarsen missed its primary endpoint in a 8,323-patient Phase III
• Amgen -10% on the read-across to its own Lp(a) drug, despite reporting positive Phase 3 lung cancer data that morning. XLV -2.52% against SPY -0.37%
• Houthi missiles and drones hit Saudi energy sites at Abha, Najran and Jizan, halting some operations and wounding 73
• The IEA says the volume of supply offline now exceeds the 1973 shock — the largest disruption in the history of the oil market. WTI $93.03, Brent near $98.50
• Core CPI ran at a 1.6% annualised rate over three months through July, its first sub-2% reading of the year — against 58% hike odds
• CRWV +11.7%, INTC +9%, QCOM +8% on an Amazon AI chip deal, BE +10% on S&P 500 inclusion; PTON -6.8%

The Bottom Line

The oil story is the bigger story and it is being told at the wrong volume. The IEA's assessment is not that this is a bad supply shock; it is that the volume of oil offline now exceeds 1973, which makes it the largest disruption in the history of the market. The S&P 500 is up 12.1% year to date anyway. That is either extraordinary resilience or an unfinished repricing, and Friday's inflation print is the first real test of which. Meanwhile the day's actual index damage came from somewhere else entirely: a Swiss drugmaker's cholesterol candidate lowered the biomarker it was designed to lower and did not save anyone, which called an entire class into question, which knocked ten percent off a company that had good news of its own that morning, which — because the Dow weights by share price rather than by anything meaningful — cost the index more than six hundred points. Two stories, one tape. Only one of them was in the headline, and it was the smaller one.

_For informational purposes only. Not investment advice._